Alphatec Holdings, Inc.
NASDAQ•ATEC
CEO: Mr. Patrick S. Miles
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2006-06-12
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Contact Information
Market Cap
$1.70B
P/E (TTM)
-11.8
24.3
Dividend Yield
--
52W High
$23.29
52W Low
$8.81
52W Range
Rank64Top 94.9%
1.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$212.93M+0.00%
4-Quarter Trend
EPS
-$0.15+0.00%
4-Quarter Trend
FCF
$9.57M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Revenue Growth Strong Total revenue reached $764.2M in 2025, marking a strong 25% increase fueled by surgeon adoption and portfolio expansion.
Operating Cash Flow Reversal Operating activities provided $45.2M cash, reversing $44.7M cash used during the preceding 2024 fiscal period.
Net Loss Significantly Narrowed Net loss narrowed to $143.4M in 2025, reflecting a favorable improvement of $18.8M compared to the prior year.
Debt Structure Optimized Issued $405.0M 2030 Notes and utilized proceeds to repurchase 80% of outstanding 2026 Convertible Senior Notes.
Risk Factors
Litigation Expense Spike Litigation costs increased 143% to $23.8M, primarily due to a shareholder settlement recorded during the 2025 fiscal year.
Intense Market Competition Operates in highly competitive segment against large, well-capitalized medical device firms with greater resources.
Regulatory Compliance Exposure Subject to extensive FDA regulation; non-compliance risks fines, product recalls, or operational restrictions.
Sales Channel Dependency Business success relies heavily on attracting and retaining qualified independent sales agents for effective market penetration.
Outlook
Compel Surgeon Adoption Focus on
Continue Clinical Innovation Continue investing in next-generation surgical approaches integrated with the expanding InformatiX platform for clinical distinction.
Expand Global Footprint Currently building profitable international footprint in select attractive markets including Australia, New Zealand, and Japan.
R&D Focus on Pathologies Prioritize developing technology platforms addressing major degenerative and deformity spine pathologies for market penetration.
Peer Comparison
Revenue (TTM)
$6.32B
$3.31B
$3.12B
Gross Margin (Latest Quarter)
165.5%
101.7%
89.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| SRRK | $5.67B | -15.0 | -145.9% | 26.9% |
| CDTX | $5.61B | -18.6 | -60.1% | 0.4% |
| CELC | $5.46B | -33.5 | -203.2% | 41.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
8.0%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:Apr 30, 2026
EPS:-$0.05
|Revenue:$197.63M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data